65 Defining migraine days 3 the use of analgesics in these additional migraine days and visualized the reported headache durations. Next, we further looked into days defined by triptan intake only (effective or not). We used Venn diagrams to visualize the proportions of migraine days for CM, HFEM and LFEM patients independently. Missing migraine characteristics in days defined by triptan intake solely (effective or not) were analyzed. Statistical differences between the groups were determined using Chi-squared tests. Linear regression analysis was used to determine the association between the number of baseline monthly migraine days and the relative number of migraine days matching the migraine criteria. The number of migraine days with effective triptan intake was compared to the total days with triptan intake. Finally, the effect of adjustment of the duration (≥4 hours or ≥30 minutes) and triptan intake (effective or not) on the number of MMD was evaluated for all four definitions. All analyses were performed in Python version 3.10.7 using statistical methods implemented in SciPy version 1.9.3. Two-sided p-values ≤ .05 were considered statistically significant. RESULTS We identified a group of n=2,021 clinically diagnosed patients with migraine, of which 199 (9.8%) were excluded due to less than 80% compliance per month. In order to be able to distinguish EM and CM patients, three consecutive months of E-diary follow-up were needed. Therefore, an additional number of 328 (16.2%) patients were removed from the dataset. This resulted in a representative dataset of n=1,494 patients with migraine. Median follow-up time was 174 (IQR 84-390) days with a mean ± SD of 6.91 ± 4.9 migraine days/month (MMD). Based on the E-diary data, patients were classified as either CM (18.9%, n=283), HFEM (48.9%, n=731) or LFEM (32.1%, n=480) (Table 2). From the total patient population 5.6% were classified as MOH patients (n=83). Baseline characteristics for the groups are presented in Table 2. Patients with CM had a mean ± SD of 13.7 ± 5.5 MMD, for HFEM and LFEM this was 6.9 ± 2.7 and 2.9 ± 1.6 MMD respectively. There was a difference in monthly acute medication days with a mean ± SD of 6.6 ± 4.6 for CM patients vs 6.2 ± 3.2 and 4.7 ± 3.1 days/month for HFEM and LFEM patients respectively (p < 0.001). Triptans were least often used by LFEM patients with a mean ± SD of 1.5 ± 1.5 days/month compared to 3.8 ± 2.6 and 3.6 ± 3.4 days/month for HFEM and CM respectively (p < 0.001).
RkJQdWJsaXNoZXIy MjY0ODMw